Gangadhara Rao sajja

Chemical engineering with +22 yrs experience of Pharma/API industry

Hyderabad, Telangana, India

About

I am a Chemical Engineer 22+years experience and currently working as an Head Technical services in Active bulk ingredients (API) . My experience in Manufacturing of API , Capacity enhancement, trouble shooting , Product scale-up , validation and commercialization, solvent recovery and recycle , cGMP audit compliance , Audit collection, process design, engineering support, and employee mentoring/training. I enjoy generating new ideas and devising feasible solutions to broadly relevant problems. Currently, I'm seeking opportunities that will allow me develop and promote technologies that benefit human life

Experience

  • specialized in Manufacturing , Tech transfer, scale-up, operational excellence , cost reduction at Lee Pharma Ltd
    Oct 2023 - Present · 2 yrs 9 mos

  • Technology Transfer, scale up, validation of onco and non onco products at shilpa medicare ltd
    Sep 2014 - Present · 11 yrs 10 mos

    working as manager in Technology transfer, scaleup, validation and delivery the product to customer as per committed timeline of Oncology and non oncology produts

  • Head -Technology transfer at shilpa medicare ltd
    Sep 2014 - Present · 11 yrs 10 mos

  • Production Specialist at Vibrant Pharmachem Pvt Ltd
    Sep 2025 - May 2026 · 9 mos

    Scale-up, Validation and commercialization Minoxidil of 4 step process. Yield improvement in cis-tosylate product. Ketoconazole API: process development and pilot batch validation. Successful completed the CMU products execution with quality and target yield.

  • Deputy General Manager at Lee Pharma Limited, Unit –I
    Oct 2023 - Jun 2025 · 1 yr 9 mos

    API Product development and scale-up, validation and commercialization and support to regulatory (DMF) filing. Active contribution of new product development like feasibility studies, lab optimization and validation, what if studies, equipment fitment, scale-up validation and commercialization. Successfully completed the US FDA audit with Zero 483 observation in February 2025. Successfully completed the ANVISA BRAZIL Regulatory audit in March 2024. Development of solvent recovery and re-used to minimize the product manufacturing cost.